Literature DB >> 25229996

Association of metabolic syndrome and hidradenitis suppurativa.

Iben Marie Miller, Christina Ellervik, Gabrielle Randskov Vinding, Kian Zarchi, Kristina Sophie Ibler, Kim Mark Knudsen, Gregor B E Jemec.   

Abstract

IMPORTANCE An association between the metabolic syndrome (MetS) and chronic inflammatory diseases, such as psoriasis or rheumatoid arthritis, has been suggested.Hidradenitis suppurativa (HS), a more localized chronic inflammation of the skin, has been speculated to have a similar association. Hidradenitis suppurativa is a substantial burden for the individual and a socioeconomic burden globally. Information about the burden of possible comorbidities is scarce.OBJECTIVE To investigate the possibility of an association between HS and MetS.DESIGN, SETTING, AND PARTICIPANTS Cross-sectional population- and hospital-based study of HS and MetS.We identified 32 patients with physician-verified HS from the outpatient clinic at the Department of Dermatology, Roskilde Hospital, and 326 patients with HS and 14 851 individuals without HS from the general population. Individuals with HS were younger,predominantly female, and more often smokers compared with the non-HS group.EXPOSURE Hidradenitis suppurativa.MAIN OUTCOMES AND MEASURES Metabolic syndrome and its components of diabetes mellitus, hypertension, dyslipidemia, and obesity.RESULTS When compared with the non-HS group, the odds ratios (ORs) for the hospital HS and population HS groups were 3.89 (95%CI, 1.90-7.98) and 2.08 (95%CI, 1.61-2.69),respectively, for MetS; 5.74 (95%CI, 1.91-17.24) and 2.44 (95%CI, 1.55-3.83), respectively, for diabetes mellitus; 6.38 (95%CI, 2.99-13.62) and 2.56 (95%CI, 2.00-3.28), respectively, for general obesity; and 3.62 (95%CI, 1.73-7.60) and 2.24 (95%CI, 1.78-2.82), respectively, for abdominal obesity. With regard to dyslipidemia, significant results were found for decreased levels of high-density lipoprotein cholesterol, with ORs of 2.97 (95%CI, 1.45-6.08) and 1.94(95%CI, 1.52-2.48) for the hospital HS and general population HS groups, respectively, when compared with the non-HS group. With regard to increased triglyceride levels, only the result for the population HS group compared with the non-HS group was significant, with an OR of1.49 (95%CI, 1.18-1.87). The OR for hypertension, which was only significant for the hospital HS group compared with the non-HS group, was 2.14 (95%CI, 1.01-4.53). Obesity and inflammation acted as possible confounders. The ORs were higher for the hospital HS group compared with the population HS group. The association between HS and MetS was not influenced by the degree of HS severity.CONCLUSIONS AND RELEVANCE As with more systemic inflammatory diseases, HS appears to be associated with MetS, indicating substantial comorbidities. Because this study is cross-sectional, causality remains to be explored.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25229996     DOI: 10.1001/jamadermatol.2014.1165

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  25 in total

Review 1.  Hidradenitis Suppurativa: Causes, Features, and Current Treatments.

Authors:  Caroline Vinkel; Simon Francis Thomsen
Journal:  J Clin Aesthet Dermatol       Date:  2018-10-01

2.  Clinical characteristics of pediatric hidradenitis suppurativa: a cross-sectional multicenter study of 140 patients.

Authors:  Peter Theut Riis; Ditte Marie Saunte; Viktoria Sigsgaard; Axel Patrice Villani; Philippe Guillem; José C Pascual; Naomi N Kappe; Annika M J D Vanlaerhoven; Hessel H van der Zee; Errol P Prens; Moetaz El-Domyati; Hossam Abdel-Wahab; Nayera Moftah; Rania Abdelghani; Eugenia Agut-Busquet; Jorge Romaní; Carol Hlela; Lerinza van den Worm; Vincenzo Bettoli; Giada Calamo; Mehmet Ali Gürer; Burcu Beksaç; Lukasz Matusiak; Amelia Glowaczewska; Jacek C Szepietowski; Lennart Emtestam; Jan Lapins; Hassan Riad Kottb; Mohammad Fatani; Lisa Weibel; Martin Theiler; Maïa Delage-Toriel; Thi Thanh Hong Lam; Aude Nassif; Pierre-Andre Becherel; Mateja Dolenc-Voljc; Nejib Doss; Dorra Bouazzi; Farida Benhadou; Veronique Del Marmol; Gregor B E Jemec
Journal:  Arch Dermatol Res       Date:  2020-03-12       Impact factor: 3.017

Review 3.  An Update on Medical Treatment Options for Hidradenitis Suppurativa.

Authors:  I E Deckers; E P Prens
Journal:  Drugs       Date:  2016-02       Impact factor: 9.546

Review 4.  [Cutaneous manifestations of metabolic syndrome].

Authors:  G Holzer; B Straßegger; B Volc-Platzer
Journal:  Hautarzt       Date:  2016-12       Impact factor: 0.751

5.  Incidence of Myocardial Infarction and Cerebrovascular Accident in Patients With Hidradenitis Suppurativa.

Authors:  Sarah Reddy; Andrew Strunk; Gregor B E Jemec; Amit Garg
Journal:  JAMA Dermatol       Date:  2020-01-01       Impact factor: 10.282

6.  Delayed Diagnosis of Hidradenitis Suppurativa and Its Effect on Patients and Healthcare System.

Authors:  Georgios Kokolakis; Kerstin Wolk; Sylke Schneider-Burrus; Stefanie Kalus; Sebastian Barbus; Susana Gomis-Kleindienst; Robert Sabat
Journal:  Dermatology       Date:  2020-07-01       Impact factor: 5.366

Review 7.  Medical and Surgical Treatment of Hidradenitis Suppurativa: A Review.

Authors:  Nicolò Scuderi; Ambra Monfrecola; Luca Andrea Dessy; Gabriella Fabbrocini; Matteo Megna; Giuseppe Monfrecola
Journal:  Skin Appendage Disord       Date:  2017-03-21

Review 8.  Hidradenitis suppurativa/Acne inversa: an endocrine skin disorder?

Authors:  Ioannis Karagiannidis; Georgios Nikolakis; Robert Sabat; Christos C Zouboulis
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

9.  In-Depth Analysis of the Hidradenitis Suppurativa Serum Proteome Identifies Distinct Inflammatory Subtypes.

Authors:  Kristina Navrazhina; Sandra Garcet; Juana Gonzalez; David Grand; John W Frew; James G Krueger
Journal:  J Invest Dermatol       Date:  2021-03-22       Impact factor: 7.590

Review 10.  Management of Hidradenitis Suppurativa in Patients with Metabolic Comorbidities.

Authors:  Ziying Vanessa Lim; Hazel H Oon
Journal:  Ann Dermatol       Date:  2016-03-31       Impact factor: 1.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.